Diversified Trust Co decreased its position in shares of Mead Johnson Nutrition Co. (NYSE:MJN) by 16.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,550 shares of the company’s stock after selling 500 shares during the period. Diversified Trust Co’s holdings in Mead Johnson Nutrition were worth $231,000 as of its most recent SEC filing.
Several other hedge funds have also recently bought and sold shares of MJN. Checchi Capital Advisers LLC raised its stake in Mead Johnson Nutrition by 2.5% in the second quarter. Checchi Capital Advisers LLC now owns 1,418 shares of the company’s stock worth $129,000 after buying an additional 35 shares in the last quarter. Baxter Bros Inc. purchased a new stake in Mead Johnson Nutrition during the second quarter worth about $218,000. East Coast Asset Management LLC. purchased a new stake in Mead Johnson Nutrition during the first quarter worth about $208,000. Eqis Capital Management Inc. purchased a new stake in Mead Johnson Nutrition during the second quarter worth about $237,000. Finally, Springbok Capital Management LLC purchased a new stake in Mead Johnson Nutrition during the first quarter worth about $222,000. Institutional investors own 96.93% of the company’s stock.
Shares of Mead Johnson Nutrition Co. (NYSE:MJN) traded up 0.98% during trading on Friday, hitting $79.01. 1,185,875 shares of the stock traded hands. Mead Johnson Nutrition Co. has a 52 week low of $65.53 and a 52 week high of $94.40. The company has a market cap of $14.59 billion, a price-to-earnings ratio of 29.73 and a beta of 1.17. The firm’s 50-day moving average price is $81.55 and its 200-day moving average price is $84.81.
Mead Johnson Nutrition (NYSE:MJN) last announced its earnings results on Thursday, July 28th. The company reported $0.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.10. The firm earned $941.50 million during the quarter, compared to analysts’ expectations of $967.25 million. Mead Johnson Nutrition had a negative return on equity of 194.30% and a net margin of 13.28%. The company’s revenue was down 8.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.76 earnings per share. On average, equities research analysts anticipate that Mead Johnson Nutrition Co. will post $3.48 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, October 3rd. Shareholders of record on Monday, September 19th will be given a dividend of $0.4125 per share. The ex-dividend date of this dividend is Thursday, September 15th. This represents a $1.65 dividend on an annualized basis and a yield of 2.09%. Mead Johnson Nutrition’s payout ratio is currently 62.03%.
A number of research firms have recently issued reports on MJN. Susquehanna reiterated a “hold” rating on shares of Mead Johnson Nutrition in a research note on Sunday, July 17th. Deutsche Bank AG set a $88.00 price objective on shares of Mead Johnson Nutrition and gave the company a “hold” rating in a research note on Sunday, July 24th. JPMorgan Chase & Co. upgraded shares of Mead Johnson Nutrition from a “neutral” rating to an “overweight” rating and set a $105.00 price objective on the stock in a research note on Tuesday, July 26th. Zacks Investment Research lowered shares of Mead Johnson Nutrition from a “buy” rating to a “hold” rating in a research note on Monday, June 13th. Finally, Citigroup Inc. lifted their price target on shares of Mead Johnson Nutrition from $100.00 to $105.00 and gave the stock a “buy” rating in a research note on Monday, July 25th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $94.83.
In other Mead Johnson Nutrition news, Director Kimberly A. Casiano sold 710 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $89.75, for a total transaction of $63,722.50. Following the completion of the sale, the director now owns 7,110 shares of the company’s stock, valued at $638,122.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Graciela Monteagudo sold 45,873 shares of the company’s stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $87.64, for a total value of $4,020,309.72. Following the sale, the senior vice president now directly owns 13,800 shares of the company’s stock, valued at approximately $1,209,432. The disclosure for this sale can be found here. Company insiders own 0.50% of the company’s stock.
Mead Johnson Nutrition Company Profile
Mead Johnson Nutrition Company (Mead Johnson) is a pediatric nutrition company. The Company manufactures, distributes and sells infant formulas, children’s nutrition and other nutritional products. The Company operates through three segments: Asia, North America/Europe and Latin America. Its product portfolio includes routine and specialty infant formulas, children’s milks and milk modifiers, dietary supplements for pregnant and breastfeeding mothers, pediatric vitamins, and products for pediatric metabolic disorders.
Want to see what other hedge funds are holding MJN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mead Johnson Nutrition Co. (NYSE:MJN).
Receive News & Ratings for Mead Johnson Nutrition Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mead Johnson Nutrition Co. and related companies with MarketBeat.com's FREE daily email newsletter.